Lpath Provides Update on Plans for iSONEP Option

               Lpath Provides Update on Plans for iSONEP Option

Management to hold webcast and conference call at 8:30 a.m. EDT, Wednesday,
October 9, 2013

PR Newswire

SAN DIEGO, Oct. 8, 2013

SAN DIEGO, Oct. 8, 2013 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the
industry leader in bioactive-lipid-targeted therapeutics, has received notice
from Pfizer Inc. that Pfizer is currently seeking to divest certain
ophthalmology R&D assets, including Pfizer's exclusive option for a worldwide
license to develop and commercialize Lpath's iSONEP™. Lpath has presented an
offer to Pfizer to reacquire these rights, and Lpath believes that a number of
third parties may have an interest in acquiring these rights as well.

iSONEP is currently being studied by Lpath in a Phase 2 clinical trial as both
monotherapy and adjunctive therapy in wet-AMD patients. A data read-out on the
study is expected in the third quarter of 2014.

"Pfizer is seeking to divest its rights to iSONEP as it continues to
strategically refocus on its core areas of expertise," stated Scott Pancoast,
president and CEO of Lpath. "Even though we value our partnership with Pfizer,
we are excited by the potential to either reacquire the rights and control
iSONEP ourselves, or work with a new partner."

About the Lpath-Pfizer Collaboration
In December2010, Lpath entered into an agreement with Pfizer that provides
Pfizerwith an exclusive option for a worldwide license to develop and
commercialize iSONEP. Under the terms of the agreement, Pfizer paid Lpath
$14million upfront and agreed to share the cost of the Nexus Phase 2 clinical
trial. Within a set period after receipt of specified Nexus data, Pfizer must
either exercise its option or forfeit its rights. If Pfizer decides to opt in,
Pfizer would: (i) pay Lpath an undisclosed amount; (ii) assume control and
financial responsibility of all subsequent studies; (iii) make future payments
totaling up to $497.5 million upon the achievement of specified development
and commercial milestones, and (iv) pay Lpath tiered double-digit royalties on
any product sales of iSONEP.

Acquisition of the iSONEP option by a third party would not affect these
terms, as the existing rights and obligations currently held by Pfizer would
either transfer to the third party or remain with Pfizer.

Webcast and Conference Call Information
Lpath will hold an investor update webcast and conference call on Wednesday,
October 9, 2013 beginning at 8:30 a.m. EDT/5:30 a.m. PDT. To listen to the
live webcast please visit the "Investor Calendar of Events" section of Lpath's
corporate website at www.Lpath.com. A webcast replay will be available
shortly after the call at the same address. To participate by phone, please
dial (877) 870-4263 (domestic callers) or (412) 317-0790 (international
callers). A telephone replay will be available afterwards by dialing (877)
344-7529 (domestic callers) or (412) 317-0088 (international callers) using
conference ID number 10035210.

About Lpath
San Diego-based Lpath, Inc. (NASDAQ: LPTN), an antibody-platform company, is
the category leader in bioactive-lipid-targeted therapeutics. Lpath's
ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic
antibodies that bind to and inhibit bioactive lipids that contribute to
disease. The company has developed three drug candidates, two of which—iSONEP™
for wet AMD and ASONEP™ for cancer—are currently being investigated in Phase 2
trials. The third candidate, Lpathomab, is an anti-LPA antibody that holds
promise in neuropathic pain and neurotrauma. For more information, visit

About Forward-Looking Statements
The Company cautions you that the statements included in this press release
that are not a description of historical facts are forward-looking statements.
These include statements regarding Pfizer's plans to divest its exclusive
option for a worldwide license to develop and commercialize iSONEP, the
Company's ability to reacquire Pfizer's exclusive option, and the Company's
ability to successfully complete additional clinical trials for iSONEP.
Actual results may differ materially from those set forth in this press
release due to the risks and uncertainties inherent in the Company's business,
including, without limitation: the results of the Company's preclinical
studies and clinical trials may not support further clinical development
and/or the commercialization of its drug candidates; the Company may not
successfully complete additional clinical trials for its product candidates on
a timely basis, or at all; the Company may fail to obtain required
governmental approvals for any its drug candidates; the Company may not be
successful in maintaining its commercial relationship with Pfizer Inc. or any
third party who acquires Pfizer's exclusive option to iSONEP; and the Company
may not be able to secure the funds necessary to support its
preclinical-development and clinical-development plans. More detailed
information about the risk factors and uncertainties that may affect the
realization of forward-looking statements is set forth in the Company's
filings with the Securities and Exchange Commission (the "SEC"), including its
Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and its other
filings with the SEC. These documents may be read free of charge on the SEC's
website at www.sec.gov. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this cautionary
statement, and the Company undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date hereof. This
caution is made under the safe harbor provisions of Section 21E of the Private
Securities Litigation Reform Act of 1995.

Scott R. Pancoast
President and CEO
Lpath, Inc.

Westwicke Partners, LLC
Stefan Loren, Ph.D.
Managing Director
(443) 213-0507

Robert H. Uhl
Managing Director
(858) 356-5932

SOURCE Lpath, Inc.

Website: http://www.lpath.com
Press spacebar to pause and continue. Press esc to stop.